Selecta Biosciences IPO

6/22/2016

IPO

$70,000,000

We expect that we will use the net proceeds from this offering for the following purposes: approximately $23 million to support the clinical development and manufacturing scale-up of SEL-212, including SEL-212's Phase 2 clinical trial; approximately $10 million to fund the start of a Phase 1 clinical trial and manufacturing scale-up of our first gene therapy program; and the remainder, if any, to fund preparations for the Phase 3 clinical trial of SEL-212 and the further advancement of our second gene therapy program as well as other potential future development programs, early-stage research and development and continued development of our SVP technologies, and for working capital and general corporate purposes.

Publicly-held

Biopharmaceutical

480 Arsenal St.
Watertown, MA 02472
USA

Selecta Biosciences, Inc. (NASDAQ: SELB) is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.